ReviewJournal of hematology & oncology2017
New development in CAR-T cell therapy.
Review in Journal of hematology & oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
212 citing papers in PubMed, 3 syntheses or guidelines pooled it, 405 citations in OpenAlex.
- Modular (universal) CAR-T platformsFrontiers in immunology · 2024Pooled it
- Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis.Annals of hematology · 2021Pooled it
- Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.Frontiers in immunology · 2021Pooled it
- Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.Leukemia · 2022Trial
- Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.Genomics, proteomics & bioinformatics · 2019Trial
- A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.Journal of hematology & oncology · 2018Trial
- Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation.Oncoimmunology · 2026Article
- Pharmacokinetic and pharmacodynamic characterization of CD8-targeted lentiviral vector forMolecular therapy. Advances · 2026Article
- Optimizing Zirconium-89 labeling for chimeric antigen receptor T cell PET imaging by comparing desferrioxamine and oxine.Scientific reports · 2026Article
- Review on Photodynamic Therapy Combined with T-Cell Immunotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Mechanisms, Challenges, and Future Directions.Current treatment options in oncology · 2026Review
- Establishment of a serum-free culture system with an optimized 5-interleukin cytokine cocktail and insulin to promote preferential CD8⁺ T-cell expansion.Bioprocess and biosystems engineering · 2026Article
- Low-dose radiotherapy remodels the tumor immune microenvironment via the cGAS-STING pathway: mechanisms, challenges, and combination therapy strategies.Molecular cancer · 2026Review
- Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment : Author List.Current treatment options in oncology · 2026Review
- Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance.Discover oncology · 2025Review
- The Neurocognitive Impact of CAR T Cell Therapy in Hematological Cancers: A Systematic Review of Cognitive Function, Quality of Life, and Psychological Outcomes.Health science reports · 2025Review
- The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years.Discover oncology · 2025Article
- IFN-γ-mediated suppression of Caspase-7 exacerbates acute lung injury induced by CAR-T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Advances in viral vector-based delivery systems for gene therapy: a comprehensive review.3 Biotech · 2025Review
- Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment.Molecular cancer · 2025Review
- The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications.Journal of hematology & oncology · 2025Review
152 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of this promising immunotherapy in B cell malignancies. In addition, this success has encountered significant hurdles in translation to solid tumors, and the safety of the on-target/off-tumor recognition of normal tissues is one of the main reasons. In this mini-review, we characterize some of the mechanisms for antigen loss relapse and new strategies to address this issue. In addition, we discuss some novel CAR designs that are being considered to enhance the safety of CAR-T cell therapy in solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.